TY - JOUR
T1 - Migrasome-mediated clearance of excess PLK4 defines a targetable vulnerability
AU - Ma, Jihong
AU - Guo, Yuhan
AU - Jiang, Yuening
AU - Wang, Qilong
AU - Bi, Meiyu
AU - Wang, Tianzhen
AU - Xiao, Yinan
AU - Zhang, Na
AU - Wang, Pan
AU - Wu, Yu
AU - Xie, Bingteng
AU - Wang, Gang
AU - Li, Mo
N1 - Publisher Copyright:
© 2026 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0/
PY - 2026/5
Y1 - 2026/5
N2 - SummaryBackgroundCentrosome amplification caused by Polo-like kinase 4 (PLK4) overexpression promotes tumour initiation, yet sustained PLK4 accumulation is detrimental to cancer cell viability. While proteasomal degradation limits PLK4 levels, whether alternative clearance mechanisms exist remains unknown.MethodsWe established inducible PLK4-overexpressing breast cancer cells and employed live-cell imaging, vesicular marker profiling, immunoprecipitation–mass spectrometry, and in vivo patient-derived xenograft models to investigate how cancer cells eliminate excess PLK4.FindingsIn this study, we identified a previously unrecognised mechanism in which excess PLK4 is rapidly expelled via migrasomes. The tetraspanin protein TSPAN6 directly binds PLK4 with high affinity and mediates its incorporation into migrasomes for extracellular release. In breast cancer samples, PLK4 expression decreased while TSPAN6 increased during progression. TSPAN6 knockdown blocked PLK4 expulsion, leading to multipolar spindle formation, apoptosis, and suppression of tumour growth and metastasis in vivo.InterpretationMigrasome-mediated clearance represents a non-proteasomal pathway maintaining centrosome homoeostasis in cancer cells. Targeting TSPAN6 to prevent PLK4 elimination selectively triggers mitotic catastrophe in PLK4-high tumours, highlighting a previously unrecognised therapeutic vulnerability.FundingThis work was supported by the National Natural Science Foundation of China (NSFC) (T2225006, T2488301, and 82272948 to ML), Beijing Municipal Natural Science Foundation (Key program Z220011 to ML, 5254051 to TW), NSFC (82371640 to BX, 82403693 to PW), and the “Clinic + X” program of Peking University (to PW).
AB - SummaryBackgroundCentrosome amplification caused by Polo-like kinase 4 (PLK4) overexpression promotes tumour initiation, yet sustained PLK4 accumulation is detrimental to cancer cell viability. While proteasomal degradation limits PLK4 levels, whether alternative clearance mechanisms exist remains unknown.MethodsWe established inducible PLK4-overexpressing breast cancer cells and employed live-cell imaging, vesicular marker profiling, immunoprecipitation–mass spectrometry, and in vivo patient-derived xenograft models to investigate how cancer cells eliminate excess PLK4.FindingsIn this study, we identified a previously unrecognised mechanism in which excess PLK4 is rapidly expelled via migrasomes. The tetraspanin protein TSPAN6 directly binds PLK4 with high affinity and mediates its incorporation into migrasomes for extracellular release. In breast cancer samples, PLK4 expression decreased while TSPAN6 increased during progression. TSPAN6 knockdown blocked PLK4 expulsion, leading to multipolar spindle formation, apoptosis, and suppression of tumour growth and metastasis in vivo.InterpretationMigrasome-mediated clearance represents a non-proteasomal pathway maintaining centrosome homoeostasis in cancer cells. Targeting TSPAN6 to prevent PLK4 elimination selectively triggers mitotic catastrophe in PLK4-high tumours, highlighting a previously unrecognised therapeutic vulnerability.FundingThis work was supported by the National Natural Science Foundation of China (NSFC) (T2225006, T2488301, and 82272948 to ML), Beijing Municipal Natural Science Foundation (Key program Z220011 to ML, 5254051 to TW), NSFC (82371640 to BX, 82403693 to PW), and the “Clinic + X” program of Peking University (to PW).
KW - Breast cancer
KW - Centriole
KW - Extracellular microenvironment
KW - Migrasome
KW - PLK4
UR - https://www.scopus.com/pages/publications/105034769444
U2 - 10.1016/j.ebiom.2026.106237
DO - 10.1016/j.ebiom.2026.106237
M3 - Article
AN - SCOPUS:105034769444
SN - 2352-3964
VL - 127
JO - eBioMedicine
JF - eBioMedicine
M1 - 106237
ER -